Sanofi to receive an up front & additional development & commercial milestones along with royalties
Rona to acquire exclusive rights globally to expand Sanofi siRNA portfolio in liver & other non-liver applications & also has the rights to develop, manufacture & commercialize the products from 4 liver-targeting preclinical programs. Sanofi gets an exclusive option for neuro & muscular disease candidates discovered using the siRNA platform for territories outside of mainland China, Hong Kong, Taiwan & Macao
The siRNA platform was developed based on novel nucleotide analogs & conjugation moieties which resulted in increased stability & in vivo duration of action, a possibility for therapeutic silencing of target genes in multiple tissue types
Ref: PRNewswire | Image: Sanofi
